A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
通过10位分析师的专业视角，深入了解拜玛林制药
Ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
过去三个月，有10名分析师提供了拜玛林制药（纳斯达克：BMRN）的评级，展示了看好和看淡的不同观点。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
以下表格概括了他们最近的评级，展示了过去30天内的情绪演变并与之前的几个月进行了比较。
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $100.7, a high estimate of $115.00, and a low estimate of $72.00. A decline of 1.17% from the prior average price target is evident in the current average.
分析师们为拜玛林制药设定了12个月的目标价，揭示了一个平均目标价为100.7美元，一个高估价为115美元，一个低估价为72美元的目标价。相较于前一个平均股价目标，目前的平均目标价下降了1.17%。
Interpreting Analyst Ratings: A Closer Look
解读分析师评级：更深入的了解
A comprehensive examination of how financial experts perceive...
最近的分析师行动...
登录免费看全文
登录/注册